Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
18.00
+0.44 (2.51%)
At close: May 22, 2026, 4:00 PM EDT
17.79
-0.21 (-1.17%)
After-hours: May 22, 2026, 4:10 PM EDT
Sensei Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
23.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Marker Therapeutics | 3.55M |
| Traws Pharma | 2.73M |
| Longeveron | 1.22M |
| Pluri | 1.08M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 454.00K |
SNSE News
- 3 days ago - Sensei Biotherapeutics Proxy statement: Proxy filing - Filings
- 3 days ago - Sensei Biotherapeutics initiated with a Buy at Citi - TheFly
- 4 days ago - Sensei Biotherapeutics Proxy statement: Proxy filing - Filings
- 10 days ago - Sensei Biotherapeutics reports Q1 EPS ($131.45) vs ($5.45) last year - TheFly
- 10 days ago - Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Business Wire
- 10 days ago - Sensei Biotherapeutics Quarterly report: Q1 2026 - Filings
- 10 days ago - Sensei Biotherapeutics Earnings release: Q1 2026 - Filings
- 20 days ago - Sensei Biotherapeutics announces first patient dosed in FTH-PIK-101 trial - TheFly